Loading...
OTCM
HTGMQ
Market cap0kUSD
Jun 25, Last price  
0.00USD
Name

HTG Molecular Diagnostics Inc

Chart & Performance

D1W1MN
OTCM:HTGMQ chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
72.12%
Rev. gr., 5y
-15.48%
Revenues
6m
-28.52%
2,480,8482,243,0723,328,9574,041,5755,132,73014,759,56721,503,89419,203,8888,548,8648,906,8286,366,220
Net income
-22m
L+25.95%
-12,774,011-11,769,419-13,958,408-21,397,791-26,039,550-18,960,017-16,453,918-19,297,664-20,870,218-17,145,170-21,594,476
CFO
-18m
L+11.50%
-8,679,934-11,823,157-12,996,616-19,243,273-22,234,208-16,572,308-13,173,918-16,695,936-16,292,377-16,508,554-18,407,791

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Based in Tucson, Arizona, HTG Molecular Diagnostics, Inc. is a life sciences company dedicated to advancing precision medicine. They provide a comprehensive suite of products, including specialized instruments, assay kit consumables, and software solutions, all designed to automate sample processing and accurately profile various molecular targets. Their extensive portfolio features numerous molecular profiling panels, such as the HTG Transcriptome Panel, HTG EdgeSeq precision immuno-oncology panel, HTG EdgeSeq miRNA whole-transcriptome assay, HTG EdgeSeq DLBCL cell of origin assay (available in both EU and non-EU versions), HTG EdgeSeq Oncology Biomarker Panel, HTG EdgeSeq ALKPlus assay EU, HTG EdgeSeq Pan B-Cell Lymphoma Panel, HTG immune response panel, and HTG mouse mRNA tumor response panel. The company directly distributes its instruments and consumables across the United States and Europe, while utilizing distributors for other international markets and specific European regions. Their diverse clientele includes biopharmaceutical companies, academic research centers, and molecular testing laboratories. Additionally, HTG Molecular Diagnostics, Inc. maintains a governing agreement with QIAGEN Manchester Limited. The company was founded in 1997 as HTG, Inc., and officially changed its name to HTG Molecular Diagnostics, Inc. in March 2011.
IPO date
May 06, 2015
Employees
53
Domiciled in
US
Incorporated in
US

Valuation

Title
in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT